Imaging techniques, such as US, are well recognized as important tools to aid early diagnosis and assess response to treatment in RA. PET offers a means of imaging the inflammatory processes of RA at a cellular level and thus may be a highly sensitive method of assessing synovitis. In this review we discuss the advantages of PET as an imaging modality for RA and summarize the existing clinical studies of PET in RA. We also highlight potentially important preclinical studies of PET in arthritis and discuss current limitations of PET as well as ongoing developments in PET technology likely to be of benefit for arthritis imaging.
Introduction
PET is a nuclear imaging modality utilizing radiolabelled ligands (radioligands) to detect and measure cellular processes in vivo. PET is performed in combination with a structural imaging modality (most commonly CT) to provide detailed cross-sectional anatomical images on which the functional information can be superimposed.
The PET tracer [
18 F]-fluoro-deoxy-glucose (FDG), a glucose analogue that identifies cells with high demand for glucose, has long had applications within the field of oncology. It is used for assisting in the diagnosis, grading and staging of a variety of malignancies and to assess response to treatment [1] . [ 18 F]-FDG PET is also now commonly used in inflammatory diseases such as vasculitis and polymyalgia, both to rule out underlying malignancy and to assess the extent and activity of the disease [2, 3] . Imaging in RA has traditionally been utilized both as an aid for diagnosis and assessment of response to treatment. Plain radiographs (X-rays) detect bony deformity, erosive bony disease and cartilage loss; often late features of arthritis. US is increasingly used to routinely detect subclinical synovitis and other soft tissue changes, such as tenosynovitis, that occur earlier in the course of disease than bony changes [7, 8] . MRI is also able to sensitively detect soft tissue changes associated with RA, such as bone marrow oedema, a predictor of erosive progression, in addition to inflammatory bone changes [9] .
Inflamed synovial tissue in RA differs widely in cellular constituents from healthy tissue, with hypertrophy of the lining layer, large quantities of infiltrating leucocytes and new blood vessel formation [1012] . Because such cellular changes precede structural changes, the ability of PET to image inflammatory cellular components in vivo makes it a potentially highly sensitive and specific means of assessing synovitis. Several studies have already shown PET may predict subsequent development of RA in patients without arthritis [13] , may predict development of joint destruction [14, 15] and can be more sensitive and specific than MRI in detecting subclinical synovitis and predicting flare in those with known RA [16] .
By predicting clinical disease course in early RA, PET could help inform decisions to commence treatment, which carry risks of adverse effects and can be costly. Through sensitive assessment of synovitis after treatment initiation, PET may be used as an early predictor of subsequent clinical response to a therapy, providing evidence for rapid escalation of or a change in treatment. This would also be useful information for drug companies testing new therapies, as it would provide a rapid means of predicting whether an experimental molecule is likely to be successful and therefore whether it should progress into larger, more expensive clinical trials. Further, PET imaging may enable tailoring of specific therapies to individual patients based on the presence of a treatment target in the individual's own synovial tissue.
A practical advantage of PET is that it can image multiple joints relatively rapidly. While an MRI assessment of all joints is impractical due to time constraints, whole body [ 18 F]-FDG PET scanning takes $30 min [17] and is a less constricting environment than an MRI scanner.
Here we summarize existing approaches to PET imaging in RA and highlight the utility of PET imaging for the detection of subclinical arthritis and assessment of response to treatment. We also discuss the limitations of PET, in addition to highlighting new developments in PET that are likely to further increase the utility of PET for the imaging of RA.
PET tracers for the imaging of RA in clinical studies
Multiple PET tracers have been investigated for their utility in imaging RA. These are outlined below and are categorized according to the function of the tracer targets. [42] . Avoiding exercise prior to the scan can negate this, but this limitation remains a potential problem in those with abnormal muscular tension or anxiety, not uncommon in patients with arthritis pain.
Markers of cellular metabolism

Markers of cell proliferation
A major histological feature of RA is the proliferation of synovial tissue, hence markers of cell proliferation may serve to detect and quantify synovitis [43] .
-choline is a precursor for biosynthesis of the cell membrane phospholipid phosphatidylcholine [44] .
Proliferating cells have a higher demand for choline than resting cells [45] , and indeed the importance of choline demand in RA has been suggested by recent RA fibroblast, SF and tissue metabolomic studies demonstrating activation of choline metabolism in RA [46, 47] . inflamed joint to be only 10 min [48] , indicating a short scan duration to detect synovitis with this tracer.
Macrophage-targeted PET
Tracers targeting cell proliferation or metabolism are obviously not specific to inflammation. Macrophages play a central role in the pathogenesis of RA [49] and macrophage infiltration is known to correlate closely with disease activity and joint erosions [50] . PET tracers targeted to cellular components highly expressed on macrophages therefore have the potential to be a highly sensitive method for the imaging of synovitis. At the 2 year follow-up, all four patients with positive hand or wrist PET findings had developed clinically apparent arthritis in those specific joints. The remaining patients (n = 25) had no signs of arthritis on baseline imaging. Of [56] after the scan compared with those who did not. In both studies, MRI scores did not distinguish between those who flared and those who did not.
Translocator protein (TSPO)targeted PET
In the most recent study, 25 patients underwent PET-CT of the hands and wrists, MRI of the same joints and were then followed up. By 1 year, 14 patients had experienced a flare, 11 had not. Of those who had a positive PET scan, 83% went on to have a flare. Of those who had a negative PET scan, 43% went on to flare. However, of the PET-negative group that did flare, all but one of these patients had flares outside of the group of joints imaged by PET [16] .
[ 11 C]PK11195 has technical limitations, chiefly due to high non-specific background signal, which makes signal quantification difficult [57] . Second-generation TSPO ligands have been developed to overcome this complication, and their widespread use for other applications (mainly in the CNS) has produced encouraging results [58, 59] . So far in arthritis there is only preclinical data, but again these are encouraging. been demonstrated to detect synovitis in two rat models of arthritis [61] . It should be noted that the binding affinity of these second-generation tracers for their target (hence tracer uptake values) is affected by a single nucleotide polymorphism in TSPO and therefore their genotype needs to be taken into account when analysing the PET data [62] .
B celltargeted PET
Multiple theories implicate B cells in RA pathogenesis [6366] , predominantly through B cell production of RF in RA synovial membrane. RF may be taken up by B cells and presented to T cells, triggering T cell activation. Further, RF may induce the activation of synovial macrophages to produce TNF-a [63] , and RF complexes may activate B cells, perpetuating B cellled inflammatory responses [63, 64] . The significance of B cells in RA pathogenesis is evidenced by the success of rituximab-induced B cell depletion as a treatment for RA [6769] , further supporting the potential of B cells as a PET tracer target.
Rituximab is a chimeric mAb targeted to CD20, a cell surface antigen highly and stably expressed on B cells [67] . Rituxumab induces B cell depletion through cell-or complement-mediated B cell destruction or promotion of apoptosis [67] . The specificity of rituximab for its target may make it a suitable imaging marker for B cells in RA synovial tissue.
Whole-body [ 124 I]-rituximab PET was undertaken in a group of five patients with active RA (as defined by a DAS28 >3.5) [70] . The majority of the cohort demonstrated accumulation of the tracer in 50% of clinically inflamed joints, but in four of five patients, tracer uptake was seen in joints not clinically swollen or tender. However, the lack of healthy controls means it is difficult to determine whether the uptake in clinically asymptomatic joints was a reflection of subclinical synovitis.
Endothelial-targeted PET
The formation of new blood vessels (angiogenesis) is essential for the expansion of synovial tissue in RA, with vessels providing a portal of entry of blood-derived leucocytes into the synovial sublining to generate and potentiate inflammation [71] . Endothelial cells themselves are thought to be targets for the action of cytokines, mitogens and permeability factors that contribute to synovitis [7275] .
The PET tracer [ 68 Ga]-PRGD2 targets a V b 3 integrin, a transmembrane heterodimeric receptor predominantly expressed on endothelial cells that mediates cell adhesion. a V b 3 integrin has been identified as a key marker of angiogenesis in RA [76] and is postulated as a therapeutic target in RA [77] ; blocking the binding site of this integrin with peptides inhibits new blood vessel formation in preclinical arthritis models [78, 79] .
Twenty patients with RA underwent whole-body PET with [ 68 Ga ]-PRGD2 was observed in the joints of two patients with OA (included as controls). However, uptake in OA was more localized to specific areas of the joint lining compared with RA joints [80] . This study did not include any disease-free controls in order to more fully establish the extent of any uptake of tracer in normal synovial tissue.
Markers of bone metabolism
Synovitis in RA is characterized by invasive destruction of underlying cartilage and bone [81, 82] . Hence markers of bony destruction may be a means of detecting inflamed joints.
]-NaF incorporates into bone by osteoclasts and osteoblasts at sites of bone formation or remodelling. 18 F ions exchange hydroxyl ions in bone crystals to form fluoroapatite [83] .
In a study of 12 RA patients, [ 18 F]-NaF and [ 18 F]-FDG PET-CT of hands was undertaken 4 days prior to biologic therapy commencement [40] . Patients were then followed www.rheumatology.oxfordjournals.org up for 6 months with tender and swollen joint counts and disease activity scoring. X-rays of the hands were taken at baseline and 6 months after commencing biologics. 
PET tracers in development for RA imaging
Multiple PET tracers have been demonstrated to accumulate in inflamed joints in animal models, but confirmation of these findings in human studies is awaited. Some of these tracers focus on key cellular components that contribute to persistent inflammation in RA, in particular macrophages, fibroblasts and endothelial cells.
Since the macrophage has a well-established pathogenic role in RA, multiple macrophage-targeted PET tracers have been tested in preclinical models of arthritis. The folate receptor is reportedly expressed with high specificity on activated macrophages and binds both folic acid and 5-methyltetrahydrofolate with high affinity [85] . In vitro data already support the abundant expression of the folate receptor on activated macrophages in synovial tissue of patients with active RA [86] . A study of [
18 F]-fluoro-PEG-folate in a rat model of arthritis demonstrated a significantly higher uptake of the tracer in arthritic vs control knees [87] . It is generally accepted that macrophages can be divided into classically activated M1-type macrophages (responsible for responding to microorganisms), which release large amounts of pro-inflammatory cytokines, and alternatively activated M2 macrophages, which release low levels of pro-inflammatory cytokines and are generally associated with tissue repair [88, 89] . It has been previously reported that M2 macrophages predominate in rheumatoid synovial tissue, especially in those with low disease activity or clinical remission [87] . CD163 is a highly specific macrophage marker found in abundance in M2 macrophages [90] , thus a tracer targeted to CD163 may be a tool for imaging rheumatoid synovitis. In a rat model, uptake of the tracer [ 68 Ga] anti-CD163 was significantly higher in arthritic paws compared with non-arthritic paws [91] . Synovial fibroblasts from patients with long-standing RA exhibit a persistently activated phenotype that potentiates inflammation and drives joint destruction [92] . Fibroblastlike synoviocytes express fibroblast activation protein 1 (FAP-1), with FAP-1 expression being higher in RA patients compared with end-stage OA, evidenced by RNA studies and staining of tissue [93] . In mice with CIA, a radiolabelled mAb was used as a PET tracer targeted to FAP-1, demonstrating increased uptake in inflamed joints compared with non-inflamed, but also significant uptake in bone [94] .
The tracer [ 18 Ga]-DOTA-Siglec 9 (sialic acid binding immunoglobulin-like lectin 9) targets the endothelial molecule vascular adhesion protein-1 (VAP-1) [95] , which is involved in leucocyte trafficking from blood into tissue [96] . Under normal conditions, VAP-1 expression on endothelium is negligible, but during inflammation its expression is dramatically increased [97] . Leucocytes adhere to VAP-1 via Siglec 9, which forms the target for PET imaging. A rabbit model study demonstrated that [ 18 Ga]-DOTA-Siglec 9 tracer was taken up to a greater extent in inflamed compared with non-inflamed knees. Further, frozen sections of human inflamed RA synovial tissue were incubated with labelled Siglec-9 peptide and stained with VAP-1. This double staining confirmed specific binding of Siglec-9 peptide to the VAP-1-positive vessels, indicating that this peptide could be of use as an endothelial imaging marker in RA [95] .
Limitations of PET
While PET offers many advantages over structural imaging, it also has some general limitations. Radioligands commonly used in research (such as [ 11 C]PK11195) are labelled with 11-C, which has a short half-life ($20 min) [16] . Although this lowers the radiation burden, such tracers need to be used at the site of manufacture, which is not financially feasible for clinical use. However, 18-Flabelled ligands have a longer half-life ($110 min) [98] and are therefore amenable for daily synthesis in a central facility and rapid transportation for use in hospitals. The poor spatial resolution of PET [99] can be problematic when imaging small joints of the hands and feet, as it becomes difficult to localize tracer uptake between small regions that are close together. The development of highresolution PET scanners specifically for the extremities will further improve the anatomical localization of the PET signal in the small joints of RA patients. This is demonstrated in a recent feasibility study where a high-resolution PET-CT scanner specifically adapted to the imaging of hands and wrists was able to quantify synovitis in patients with RA using [ 18 F]-FDG PET [100] . Another significant limitation of PET is that it requires imaged subjects to be exposed to radiation, from both the PET tracer itself and the anatomical CT scan. However, the half-life of many new tracers is short and the radiation exposure associated with a PET-CT scan is in the same range as many CT scans used routinely in clinical practice [16] . By employing low-resolution CT during the PET scan, the radiation dose can be minimized.
The advent of PET-MRI will serve to further lower the radiation dose received by patients undergoing PET. In addition, ongoing developments resulting in increasingly sensitive PET scanners will mean a further reduction in the dose of administered PET tracer required to detect synovitis.
PET-MRI
PET is commonly combined into a signal gantry with a CT component to provide complimentary structural imaging upon which the PET data are superimposed. However, for RA, MRI offers major advantages over CT, including detection of synovitis and bone oedema. Currently PET data are combined with MR images obtained from a separate scan. While PET and MRI images can be co-registered, inevitably there is misalignment in both space and time vs if the images are obtained by a single combined PET-MRI scanner. As well as negating the need for a separate MRI, PET-MRI scanners offer the further advantage of lower radiation exposure, as CT is no longer needed.
PET-MRI availability is currently limited since the units are expensive and few centres have them. As the demand for nuclear imaging in musculoskeletal diseases increases, we anticipate PET-MRI will become increasingly commonplace. The feasibility of PET-MRI for hand and wrist imaging is indicated by Miese et al. [27] , where increased [ 18 F]-FDG uptake was found at the sites of synovitis and also tenosynovitis on PET-MRI of the hands and wrists.
Conclusion
There is growing evidence to support the utility of PET in the early detection and accurate quantification of synovitis, as well as its utility in providing a rapid readout of response to treatment in RA patients. Studies of TSPO PET, in particular, demonstrate how PET may predict the likelihood of persistent synovitis and thus allow for early diagnosis, predicting flare in patients with an established diagnosis and also predicting who may go on to develop joint destruction. There remains huge potential to develop tracers targeting specific molecular components of the inflammatory process, with the opportunity to utilize PET to better understand the molecular basis of disease and to predict and monitor response to treatment.
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